Nichols W C, Elsaesser V E, Pankratz N, Pauciulo M W, Marek D K, Halter C A, Rudolph A, Shults C W, Foroud T
Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave., Cincinnati, OH 45229, USA.
Neurology. 2007 Oct 30;69(18):1737-44. doi: 10.1212/01.wnl.0000278115.50741.4e. Epub 2007 Sep 5.
Pathogenic mutations in the leucine-rich repeat kinase 2 gene (LRRK2) have been found to cause typical, later-onset Parkinson disease (PD). Although G2019S is the most common mutation, other mutations have also been reported. It is critical to catalog the types of mutations found in LRRK2 that can cause PD, so as to provide insight regarding disease susceptibility and potential novel treatments.
We performed a comprehensive study of all 51 exons of the LRRK2 gene in one PD patient from each of 88 multiplex PD families who had the highest family-specific multipoint lod score at the LRRK2 locus from a cohort of 430 PD families without the G2019S mutation.
Five families (5.7%) harbored what seem to be novel, pathogenic mutations (L1795F, I1192V, E10K, E334K, Q1111H). Three of these apparent mutations were in known, functional domains of the LRRK2 protein, where other studies have also identified disease producing mutations. However, two of the novel variants were found in the N-terminal region of LRRK2, where no pathogenic substitutions have yet been reported. Similar to previous studies, all subjects with an LRRK2 mutation had classic symptoms of PD and typical, later age at onset.
We have identified five novel variants in LRRK2, with two of these in the N-terminal region of LRRK2, where no pathogenic substitutions have been previously reported. If confirmed to be causative, these mutations would broaden the potential mechanisms whereby mutations in LRRK2 result in Parkinson disease.
富含亮氨酸重复激酶2基因(LRRK2)中的致病性突变已被发现可导致典型的晚发性帕金森病(PD)。虽然G2019S是最常见的突变,但也有其他突变的报道。对LRRK2中发现的可导致PD的突变类型进行编目至关重要,以便深入了解疾病易感性和潜在的新治疗方法。
我们对来自430个无G2019S突变的帕金森病家系队列中,在LRRK2基因座具有最高家族特异性多点对数记分的88个多病例帕金森病家系中的每一个家系的1名帕金森病患者的LRRK2基因的所有51个外显子进行了全面研究。
5个家系(5.7%)存在似乎是新的致病性突变(L1795F、I1192V、E10K、E334K、Q1111H)。其中三个明显的突变位于LRRK2蛋白已知的功能结构域,其他研究也在这些区域鉴定出了致病突变。然而,两个新的变异体在LRRK2的N端区域被发现,该区域尚未报道有致病性替代。与先前的研究相似,所有携带LRRK2突变的受试者都有帕金森病的典型症状且发病年龄较晚。
我们在LRRK2中鉴定出5个新的变异体,其中两个在LRRK2的N端区域,此前该区域尚未报道有致病性替代。如果被证实具有致病性,这些突变将拓宽LRRK2突变导致帕金森病的潜在机制。